Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated ...

Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal studyBRISBANE, Calif., Sept. 18, 2024 ...

Scotiabank has recently initiated Tempest Therapeutics Inc (TPST) stock to Sector Outperform rating, as announced on March 14, 2024, according to Finviz. Analyst ratings are significant because they ...

In a report released today, George Farmer from Scotiabank maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report), ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Study findings support tivozanib monotherapy for second-line treatment of certain patients with metastatic RCC, an expert ...

The phase 3 TiNivo-2 study (NCT04987203), which evaluated the combination of nivolumab (Opdivo) and tivozanib (Fotivda) in ...

In a report released today, George Farmer from Scotiabank maintained a Buy rating on Aura Biosciences Inc (AURA – Research Report), with ...

Tempest Therapeutics Inc (NASDAQ: TPST) has experienced a rise in its stock price by 5.04 compared to its previous closing price of 1.19. However, the company has seen a fall of -6.72% in its stock ...

(MENAFN- GlobeNewsWire - Nasdaq) BRISBANE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology ...

Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated ...